Sunday, August 31, 2008

FIBROMYALGIA COMMERCIAL BONANZA?

With a considerable patient potential and large medical unmet need, the untapped fibromyalgia market represents a lucrative opportunity for pharmaceutical companies. Estimated to total around $650m in 2007 in the seven major markets.

The approval of Pfizer's Lyrica transformed the previously unchartered fibromyalgia market and provided a new level of validity for this disputed condition.

In June 2008, Eli Lilly's dual serotonin and norepinephrine reuptake inhibitor (SNRI) Cymbalta (duloxetine) became the second FDA approved fibromyalgia treatment. [read more]

Posted by Antonio Howell, M.D. at 8/31/2008 09:34:00 PM

Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Disclaimer:

This publications contains the opinions and ideas of its author(s). It is intended to provide helpful and informative material on the subjects addressed. It is written with the understanding that the author(s) is (are) not engaged in rendering medical, health, or any other kind of professional service(s). The reader should consult his or her medical, health or other competent professional before adopting any of the suggestions. The author(s) specifically disclaim all responsibility for any liability, loss, or risk, personal or otherwise, which is incurred as a consequence, directly or indirectly, of the use and application of any of the contents of this site.